| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Q32 Bio Inc.$15.21
+0.25 (+1.65%)
C 40Pipeline Score Fair Value Biotech · Clinical
Market Cap
98.35 M
EPS
2.67
P/E Ratio
2.18 $
Value Trade
6.46 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.22 M
Operating CF
-6.34 M
Total Assets
63.67 M
Total Liabilities
17.36 M
Equity
46.31 M
D/E Ratio
12,345
-5.69 %
Week
-10.77 %
1 Month
40.1 %
3 Month
200.52 %
6 Month
-94.93 %
5 Year
-98.6 %
All Time
Cash Data
Cash Position
50.75 M
Monthly Burn
2.11 M
Runway
21.2 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
527.40 K
52 Week Range
1.35 - 8.05
% held by Insiders
59.87 %
% held by Institutions
39.85 %
Enterprise Value
61.24 M
Total Shares
23.72 M
Short %
18.39 %
Float Shares
12.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Q32 Bio Inc.
163Total events
3Upcoming
38Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T1Full Results
Subscribe to view catalyst details
Event history 2
TBD
◆Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | bempikibart | Phase 2a topline data readout | Phase 2a | — | – | – | – |
2026-06-30 | bempikibart | Phase 2a topline data readout | Phase 2a | — | – | – | – |
2026-06-30 | bempikibart | Phase 2a topline data readout | Phase 2a | — | – | – | – |
Drug Pipeline Intelligence
C40
Pipeline Score $76M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored2.6x
rNPV / MCap Top 59%
Micro Cap (rank 375 of 913)
Percentile RankQ32 Bio Inc. carries a moderate pipeline score (40/100), with $1.1B risk-adjusted pipeline value, led by ADX-097 in IgA Nephropathy (Phase 2), across $72B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX-097 Small molecule | IgA Nephropathy | Phase 2 | NCT06419205 | 16% | $636M | NOT YET_RECRUITING | 30 | VERY_FAST | D (20) | Feb 1, 2028 | - | Jul 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bempikibart Fast Track | alopecia areata | Phase 2a | 2026-07-13 | mean reduction SALT: 35.3%; SALT 20 response m ITT: 40.0%; SALT 20 response ITT: 30.3% Read More | Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Read More | |
bempikibart Fast Track | alopecia areata | Phase 2a | 2026-07-13 | mean reduction SALT: 35.3%; SALT 20 response m ITT: 40.0%; SALT 20 response ITT: 30.3% Read More | Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Read More | |
bempikibart Fast Track | alopecia areata | Phase 2a | 2026-07-13 | mean reduction SALT: 35.3%; SALT 20 response m ITT: 40.0%; SALT 20 response ITT: 30.3% Read More | Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QTTB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QTTB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QTTB▼ -15%on this news
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio has announced a public offering of 6,027,399 shares of common stock priced at $18.25 each, along with pre-funded warrants. The offering aims to raise approximately $200 million for working capital, including advancing their treatment bempikibart for alopecia areata. The offering is expected to close on July 16, 2026, pending customary conditions.
Read more →QTTB▼ -13.7%on this news· ran to -30% by day 3shared move
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio Inc. has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The funds will support clinical development, particularly for bempikibart, a treatment for alopecia areata. The offering is subject to market conditions, and the company has granted underwriters a 30-day option for additional shares.
Read more →QTTB▲ +90.7%on this newsshared move
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Q32 Bio announced positive results from Part B of the SIGNAL-AA clinical trial, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Notably, 40% of patients achieved a SALT-20 response at Week 36. The treatment demonstrated a favorable safety profile and supports further development towards a registration-directed program in 2027.
Read more →QTTB▲ +90.7%on this newsshared move
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Q32 Bio Inc. will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata on July 13, 2026. The company will host a conference call to discuss these results, highlighting its focus on innovative therapies for autoimmune diseases. Bempikibart is designed to re-regulate immune function in patients with severe alopecia areata.
Read more →QTTB▲ +81.2%on this news
Q32 Bio Announces $55 Million Private Placement Financing
Q32 Bio Inc. has announced a private placement financing of approximately $55 million, involving the sale of common stock and pre-funded warrants. The placement is expected to close on May 28, 2026, and will support the company's ongoing development of therapies for alopecia areata and other autoimmune diseases. The financing is led by BVF Partners L.P. and includes participation from several institutional investors.
Read more →QTTBQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported its first quarter 2026 financial results, highlighting significant progress in its SIGNAL-AA Phase 2 clinical trial for bempikibart. The company announced that the first patient has been dosed in the Part B open-label extension and is on track to release topline data by mid-2026. Additionally, Q32 Bio raised $10.5 million through a registered direct offering, strengthening its financial position.
Read more →QTTB▼ -7.3%on this news
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Q32 Bio Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company focuses on developing therapies for alopecia areata and other autoimmune diseases. Management will engage in a fireside chat, and a webcast will be available on their website. The company is advancing its Phase 2 program for bempikibart, an innovative treatment for alopecia areata.
Read more →QTTB▲ +17.5%on this news· ran to +35% by day 1
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand;
Q32 Bio reported its fourth quarter financial results for 2025, highlighting the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial and an increase in its patient size to 33 based on demand. The company also completed a registered direct offering worth $10.5 million and sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics. The upcoming topline results from the clinical trial are expected in mid-2026, and Q32 Bio emphasizes the promising signs for its drug candidate, bempikibart, in treating alopecia areata.
Read more →QTTB▼ -5.4%on this news
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Q32 Bio Inc. (Nasdaq: QTTB) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference scheduled for February 25, 2026. The company, focused on innovative therapies for autoimmune diseases, will present a fireside chat as part of the event. Q32 Bio is developing bempikibart (ADX-914), an anti-IL-7Rα antibody, to address alopecia areata, a condition affecting approximately 700,000 people in the U.S. The presentation will be accessible through the company's website, allowing for wider audience engagement.
Read more →QTTB▲ +9.7%on this news· ran to +20% by day 3shared move
Q32 Bio Announces $10.5 Million Registered Direct Offering
Q32 Bio has announced a $10.5 million registered direct offering, primarily aimed at advancing its clinical programs for alopecia areata and other autoimmune diseases. The offering involves the sale of shares and pre-funded warrants, led by new and existing institutional investors. Q32 Bio plans to use the net proceeds for working capital and to support future clinical trials of its therapy, bempikibart. The company acknowledges inherent risks in clinical trials that may affect its performance and shareholder value.
Read more →QTTB▲ +74.4%on this news
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront, with potential total payments up to $592 million. This strategic move aims to enhance Q32 Bio's focus on advancing bempikibart for alopecia areata. The company retains its tissue-targeted complement inhibitor platform and continues to evaluate options for its remaining assets.
Read more →QTTB▲ +74.4%on this newsshared move
Q32 Bio Sells Complement Inhibitor ADX-097 -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments exp
Q32 Bio announced the sale of its complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront and guaranteed milestone payments. This transaction is expected to strengthen Q32's financial position, extending its cash runway into the second half of 2027. The company will continue to focus on advancing bempikibart, its candidate for treating alopecia areata, with topline results from the SIGNAL-AA Phase 2a trial anticipated in mid-2026. Q32 Bio retains rights to its tissue-targeted complement inhibitor platform and will evaluate strategic options for its remaining assets.
Read more →QTTB▼ -9.1%on this news
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio reported its third quarter 2025 financial results, highlighting the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, which has been expanded to 33 patients. The company noted encouraging early signs of clinical activity and a strong financial position with $49 million in cash. Topline data is expected in mid-2026.
Read more →QTTB▼ -10.8%on this news
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio has completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart, an anti-IL-7Rα antibody targeting alopecia areata. The trial exceeded its initial enrollment target, reflecting high demand. Preliminary data suggest early signs of clinical activity, with topline results expected in mid-2026, potentially leading to pivotal trials.
Read more →QTTBQ32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio Inc. will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 4th. The company focuses on developing therapies for alopecia areata and other autoimmune diseases. A webcast of the event will be available on their website, with archived replays accessible for 90 days.
Read more →QTTBxfeff; Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update -- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout
Q32 Bio reported its financial results for the second quarter of 2025, highlighting ongoing patient dosing in its SIGNAL-AA Phase 2a clinical trial. The company appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to enhance its leadership team. With cash reserves of $54.8 million, Q32 Bio expects to maintain its operations into 2027 while preparing for topline data readout from Part B of the trial in the first half of 2026. Despite a decrease in net loss compared to the previous year, significant research and development expenses persist as the company continues to navigate clinical trials.
Read more →QTTBQ32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Inc. reported positive financial results for Q2 2025, showcasing ongoing patient dosing in its SIGNAL-AA Phase 2a trial. The company announced a cash balance of $54.8 million as of June 30, 2025, allowing operations to continue into 2027. Notably, Adrien Sipos was appointed as the Interim Chief Medical Officer, bringing significant immunology expertise. The firm is on track for topline data from Part B of the SIGNAL-AA trial in the first half of 2026.
Read more →QTTBQ32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio has appointed Dr. Adrien Sipos as Interim Chief Medical Officer, succeeding Dr. Jason Campagna. Dr. Sipos brings over 25 years of experience in immunology and clinical development. She will lead efforts in advancing bempikibart, a novel treatment for alopecia areata, as the company progresses through its Phase 2a clinical trial.
Read more →QTTBQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update -- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part
Q32 Bio (QTTB) announced its financial results for Q1 2025 and provided updates on its clinical trials. The company reported dosing the first patients in both Part A and Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart, which has received Fast Track designation for alopecia areata. Financially, Q32 Bio has a cash balance of $65.5 million, sufficient to support operations into the second half of 2026, although it reported a net loss this quarter compared to a profit in the same period last year. The topline data readout for the trial is expected in the first half of 2026.
Read more →QTTBQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Q32 Bio has received FDA Fast Track designation for bempikibart (ADX-914), aimed at treating alopecia areata. This designation underscores the significant unmet medical need for effective therapies in this area. The drug, currently in Phase 2 trials, is designed to modulate immune function and has shown promising clinical activity. Q32 Bio aims to expedite development and regulatory review in collaboration with the FDA.
Read more →QTTB▼ -8.2%on this news
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio has announced the successful dosing of the first patients in both Part A open-label extension and Part B of the SIGNAL-AA Phase 2a trial for bempikibart, aimed at treating alopecia areata. The trial demonstrates encouraging preliminary data, showing potential long-term efficacy and safety of the therapy. The company expects to report topline results from Part B in the first half of 2026, but acknowledges potential risks that may impact the trial's outcomes.
Read more →QTTB▼ -7.8%on this news
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update -- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlightin
Q32 Bio reported its fourth quarter 2024 financial results and provided updates on its bempikibart clinical program for alopecia areata. The company presented encouraging Phase 2a Part A data at the 2025 AAD meeting, highlighting the treatment's potential for durable responses and a favorable safety profile. With $78 million in cash, Q32 Bio is well-positioned to advance further trials, aiming to initiate SIGNAL-AA Part B in H1 2025 and expecting topline results in H1 2026. The increase in R&D expenses reflects the ongoing investment in clinical trials.
Read more →QTTB▼ -7.2%on this newsshared move
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting Results presented in AAD late-breaker demonstrate
Q32 Bio presented promising results from its SIGNAL-AA Part A clinical trial at the 2025 AAD Meeting, showcasing the efficacy of bempikibart in treating severe alopecia areata. The trial reported significant improvements in SALT scores at week 24 and evidence of continued benefits beyond treatment cessation. Both safety and tolerability of bempikibart were confirmed, with no serious adverse events observed. The company plans to advance the bempikibart program with an open-label extension study and the initiation of SIGNAL-AA Part B in the first half of 2025.
Read more →QTTBQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio Inc. announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata will be presented at the 2025 American Academy of Dermatology Annual Meeting. This trial evaluates bempikibart, a fully human anti-IL-7Rα antibody, for its potential in treating severe alopecia areata. The CEO emphasized the recognition of the trial's promising clinical data and the enthusiasm surrounding the treatment, which aims to address a significant unmet need in patient care.
Read more →QTTB▼ -5.3%on this newsshared move
Q32 Bio to Participate in Upcoming March Investor Conferences
Q32 Bio Inc. announced its participation in two investor conferences scheduled for March 2025. The TD Cowen 45th Annual Health Care Conference will be held on March 5, followed by the Leerink Partners Global Healthcare Conference on March 11. These events will feature presentations from management, highlighting the company's advancements in biologic therapeutics aimed at restoring immune balance in autoimmune diseases. Q32 Bio is currently developing bempikibart, a promising treatment under evaluation in a Phase 2 program.
Read more →QTTBQ32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata -- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rat
Q32 Bio has announced a strategic restructuring focused on advancing its drug bempikibart for alopecia areata treatment. The company will discontinue its renal basket trial for ADX-097 and prioritize resources on bempikibart, which has shown promising results in clinical trials. The restructuring is expected to extend the company's cash runway to the second half of 2026 and initiate an open-label extension of the ongoing clinical trial. Q32 Bio anticipates reporting topline data from Part B of the SIGNAL-AA trial in the first half of 2026.
Read more →QTTB▲ +7.9%on this news
Q32 Bio to Participate in Oppenheimer
Q32 Bio Inc. (Nasdaq: QTTB) announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference scheduled for February 11, 2025. The company, focused on developing biologic therapeutics to restore immune homeostasis, aims to provide insights into its ongoing Phase 2 programs. These programs address immune disorders by targeting the IL-7/TSLP receptor pathways and the complement system. Interested stakeholders can access the presentation via a webcast on Q32 Bio's website.
Read more →QTTB▼ -7.2%on this news
Building The Future of Immune Therapeutics Company Overview January 2025 Forward Looking Statements This presentation has been prepared by Q32 Bio Inc. ("we", "us," "our," "Q32" or the "Company") and is made for informat
Q32 Bio Inc. has provided an overview of its forward-looking statements regarding the development of its immune therapeutics, particularly focusing on Bempikibart for alopecia areata. The presentation highlights the anticipated Phase 2a Part B trials expected to begin in the first half of 2025, with significant milestones anticipated in subsequent years. The company emphasizes its innovative therapeutic developments alongside a focus on safety and clinical efficacy, while acknowledging various risks including funding availability and regulatory hurdles. The efficacy shown in initial trials positions Q32 favorably in a competitive landscape.
Read more →QTTB▲ +7.7%on this news· ran to -84% by day 3
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA
Q32 Bio announced positive topline results from the SIGNAL-AA Phase 2a clinical trial for bempikibart, an IL-7R inhibitor, demonstrating significant clinical activity in patients with alopecia areata. The company plans to expand this trial by enrolling more patients after reporting a safe and well-tolerated profile for the drug. However, the SIGNAL-AD trial for atopic dermatitis did not achieve its primary endpoint, leading to plans for further review. Despite this, biomarker data from both trials indicate strong target engagement and the potential for bempikibart as a new treatment option.
Read more →QTTBQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data fr
Q32 Bio reported financial results for Q3 2024, highlighting that bempikibart's Phase 2 trials in atopic dermatitis and alopecia areata are on schedule, with topline results expected in December. The company's financial position remains strong, with $89.1 million in cash, projected to support several upcoming clinical milestones. Alongside, the ongoing development of ADX-097 is showing initial positive safety results. However, the company also faced a net loss of $17.6 million and a significant rise in operational expenses.
Read more →QTTBQ32 Bio to Participate in Guggenheim
Q32 Bio Inc. will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA. The company is focused on developing biologic therapeutics aimed at restoring immune balance in autoimmune and inflammatory diseases. Q32's lead programs are focused on regulating the IL-7 and TSLP receptor pathways to re-balance immunity. They are also assessing their adaptive immunity program, bempikibart, in two Phase 2 trials for atopic dermatitis and alopecia areata.
Read more →QTTBQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Q32 Bio announced that it will present positive results from its Phase 1 trial of ADX-097 at the upcoming ASN Kidney Week 2024. The trial demonstrated that ADX-097, a tissue-targeted complement inhibitor, was well-tolerated and showed favorable pharmacokinetic and pharmacodynamics properties. The upcoming presentation will support continued advancement into Phase 2 trials for renal diseases associated with complement activation. This novel approach aims to inhibit complement directly in diseased tissues while minimizing systemic effects, enhancing safety profiles.
Read more →QTTBQ32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio Inc. announced its management's participation in three significant investor conferences scheduled for September 2024, including the Morgan Stanley 22nd Annual Global Healthcare Conference. The company is focused on developing biologic therapeutics to rebalance immune functions, with lead programs addressing autoimmune diseases. Important presentations will occur at the Cantor Fitzgerald Global Healthcare Conference and the Stifel 2024 Virtual Immunology and Inflammation Summit, with webcasts available for wider access. This engagement highlights the company's effort to communicate its advancements and collaborations in the biotechnology sector.
Read more →QTTB▼ -10.6%on this news
Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update -- Completed enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial and increased trial size to 121 patients based on P
Q32 Bio has reported its financial results for Q2 2024, highlighting significant progress in its clinical trials, particularly for bempikibart in atopic dermatitis and alopecia areata, with expected topline results by Q4 2024. The company completed enrollment in these trials, exceeding its initial patient target due to high demand. Furthermore, Q32 Bio has a solid financial position, with over $107 million available to fund operations into mid-2026. However, the company reported a substantial increase in net loss and research expenditures compared to the previous year.
Read more →QTTB▲ +7.9%on this news· ran to +38% by day 3
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis -- Exceeded enrollment target due to patient demand; trial size increased to 121 patients -- -- Bemp
Q32 Bio has successfully completed enrollment for its SIGNAL-AD Phase 2 clinical trial of bempikibart, having surpassed the initial target due to high patient demand, resulting in a total of 121 participants. The study aims to evaluate the efficacy and safety of bempikibart in adults with moderate-to-severe atopic dermatitis, with topline results anticipated in the fourth quarter of 2024. This milestone, along with the successful completion of enrollment for the SIGNAL-AA trial in alopecia areata, indicates significant progress for the company in its clinical development efforts.
Read more →QTTB▲ +5.7%on this news
Q32 Bio Joins Russell 3000® Index
Q32 Bio Inc. has announced its inclusion in the Russell 3000 Index, effective July 1, 2024. This membership highlights the company's growth and aligns with its ongoing development of biologic therapeutics aimed at treating autoimmune and inflammatory diseases. President Lee Kalowski expressed optimism regarding future milestones and expanding the shareholder base. The Russell 3000 Index is a key benchmark for institutional investors, enhancing Q32 Bio's market visibility and credibility in the biopharmaceutical sector.
Read more →QTTBQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in
Q32 Bio announced its first-quarter 2024 financial results and a corporate update, highlighting the completion of enrollment for its bempikibart Phase 2 clinical trials in alopecia areata (AA) and atopic dermatitis (AD), with topline data expected in Q4 2024. The company, which became public through a reverse merger with Homology Medicines, reported cash reserves of $135.3 million, anticipated to support its clinical milestones through mid-2026. Despite increased operational costs, the company remains optimistic about its pipeline advancements and the initiation of further clinical trials.
Read more →QTTBQ32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Q32 Bio Inc. has appointed Lee Kalowski as President and Chief Financial Officer, a position he has held in an interim capacity for the past five months. Kalowski brings over two decades of experience in the biopharmaceutical sector, contributing significantly to the company's strategic and financial operations. Under his leadership, Q32 Bio aims to advance its clinical programs, including bempikibart and ADX-097, in the treatment of autoimmune diseases. This appointment comes as the company transitions into a publicly traded entity, highlighting its developmental ambitions in the biotech industry.
Read more →QTTBCONFIDENTIAL Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alop
Q32 Bio has successfully completed its merger with Homology Medicines and raised $42 million in private placements, aiming to enhance its clinical focus on bempikibart and ADX-097 for conditions like atopic dermatitis and alopecia areata. The new company will operate under the ticker QTTB, with expected cash reserves sufficient to support operations through mid-2026. Topline results from ongoing Phase 2 trials for both bempikibart and ADX-097 are anticipated in late 2024 and 2025, respectively.
Read more →QTTBQ32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Q32 Bio has successfully completed its merger with Homology Medicines and will begin trading under the ticker symbol QTTB starting March 26, 2024. The merger is accompanied by a $42 million private placement, providing Q32 Bio with approximately $130 million to fund operations through mid-2026. Key clinical trials for its lead candidates, bempikibart and ADX-097, are in progress, with topline results anticipated in 2024 and 2025, addressing significant unmet medical needs in autoimmune diseases.
Read more →QTTBQ32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases
Q32 Bio has published new preclinical data demonstrating the efficacy of ADX-097, a tissue-targeted complement inhibitor. The findings indicate that the drug effectively modulates local tissue complement, which may improve treatment for various complement-mediated diseases. Q32 Bio plans to initiate Phase 2 clinical trials for renal diseases and ANCA-Associated Vasculitis, with initial data expected by late 2024. This approach addresses the limitations of systemic treatments that increase infection risks.
Read more →QTTBBuilding The Future of Immune Therapeutics Company Overview January 2024 Disclaimers Important Information for Investors This confidential presentation (Presentation) is for informational purposes only and is being provi
The presentation outlines a proposed business combination between Q32 Bio Inc. and Homology Medicines, Inc. that is in the early stages of planning. It includes disclaimers about the confidentiality of the information and the need for investor caution. Forward-looking statements include potential risks related to obtaining approvals and regulatory clearances, which may affect the transaction's timeline and success. This potential deal comes with various uncertainties that could impact both companies' operations and financial performance.
Read more →QTTBHomology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency Homology Medicines has an initial 180-day period through
Homology Medicines, Inc. announced that it has received a notification from Nasdaq regarding a deficiency in its minimum bid price requirement. The notification states that the company's common stock price has been below $1.00 for the last 30 consecutive business days. Homology has a 180-day compliance period, until June 26, 2024, to regain compliance, which may involve a reverse stock split in connection with its proposed merger with Q32 Bio Inc. Failure to comply could result in delisting, although the company may appeal such a decision.
Read more →QTTBQ32 Bio and Homology Medicines Announce Merger Agreement The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for
Q32 Bio and Homology Medicines have announced a merger agreement to form a new entity operating under the name Q32 Bio Inc. This merger, approved by both companies' boards, aims to advance the development of Q32 Bio's clinical candidates, particularly bempikibart and ADX-097, both targeting immune disorders. Q32 Bio will secure a $42 million private placement to support its clinical programs, with a projected cash balance of approximately $115 million post-merger. The combined entity is poised for growth, focusing on treatments for autoimmune diseases, and is expected to close in the first quarter of 2024.
Read more →QTTBQ32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
Q32 Bio has announced the regaining of worldwide development and commercialization rights to bempikibart (formerly ADX-914) from Amgen. The re-acquisition strengthens Q32 Bio's portfolio in autoimmune disease therapies and is particularly focused on atopic dermatitis and alopecia areata, both of which are in ongoing Phase 2 trials. Q32 Bio plans to report topline Phase 2 results in the latter half of 2024 following the trials. This step marks a significant advancement for the company in its strategic objectives and product development efforts.
Read more →QTTBQ32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
Q32 Bio has appointed Dr. Saul Fink as Chief Technology Officer, highlighting his extensive leadership in CMC operations. He will oversee the company's chemistry, manufacturing, and control-related activities, essential for developing biologic therapeutics. Q32 Bio aims to advance treatments for autoimmune and inflammatory diseases, with its lead programs addressing significant immune system dysregulation. Dr. Fink's prior experience includes roles at Normunity and Bristol-Myers Squibb, making him a valuable addition as the company scales its operations.
Read more →QTTBCopyright 2023 Homology Medicines, Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We
Homology Medicines has presented forward-looking statements regarding the progress and potential of its gene therapy and gene editing platforms, including the investigational gene editing candidate HMI-103 for phenylketonuria (PKU). The company states that there is a significant unmet medical need for PKU treatments and presents a substantial market opportunity. However, it acknowledges various risks, such as ongoing financial losses and potential setbacks in clinical trials, which may affect its future developments and success.
Read more →QTTBQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
Q32 Bio and Horizon Therapeutics have announced the dosing of the first patient in a Phase 2 clinical trial for bempikibart, aimed at treating severe alopecia areata. This trial marks a critical step in evaluating the drug's efficacy in re-regulating immune functions linked to the condition. Alopecia areata is a significant autoimmune disorder with unmet medical needs, and both companies are committed to advancing this treatment. In addition to this trial, bempikibart is also undergoing evaluation for atopic dermatitis.
Read more →QTTBForward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the
The presentation outlines forward-looking statements regarding the company's genetic medicine developments and therapeutic strategies. It highlights the potential of their gene therapy and gene editing platforms, including the GTx-mAb platform. While the firm emphasizes its leadership in the field and plans for upcoming clinical milestones, it also acknowledges several financial and operational risks that could affect its progress. The company is actively pursuing collaborations and aims to advance its pipeline of genetic medicine candidates.
Read more →QTTBQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomi
Read more →QTTBQ32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition
--Jodie Morrison appointed as Board Member and Acting CEO-- WALTHAM, Mass., Sept. 20, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board M
Read more →QTTBQ32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
WALTHAM, Mass. and DUBLIN, Aug. 15, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and op
Read more →QTTBQ32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097
Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition WALTHAM, Mass., June 23, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic
Read more →QTTBShelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia "Resolution of Inflammation" Conference
Dr. Violette also the co-organizer of the "Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies" conference at the Keystone Symposia WALTHAM, Mass., June 8, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to re
Read more →QTTBQ32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders
First clinical-stage program from Q32 Bio's tissue targeted complement inhibitor platform Clinical-stage pipeline now consists of two programs in development to restore immune homeostasis WALTHAM, Mass., May 26, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology compa
Read more →QTTBHOMOLOGY MEDICINES, INC. UNAUDITED CONDENSED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION On
HOMOLOGY MEDICINES, INC. UNAUDITED CONDENSED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION On March 10, 2022, Homology Medicines, Inc. ( Homology or the Company ) closed the previously announced transaction (the Transaction ) with Oxford Biomedica Solutions LLC (f/k/a Roadrunne
Read more →QTTBHomology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU BEDFORD, Mass., February 18, 2022 Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has notified the compa
Read more →QTTBOxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner Oxford Biomedica and Homology Medicines to es
Read more →QTTBQ32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021
CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data for the Company's lead program for innate immunity, ADX-097. Three posters were present
Read more →QTTBQ32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021
CAMBRIDGE, Mass., Nov. 8, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data from the Company's lead program for innate immunity, ADX-097, presented at the American
Read more →QTTBQ32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021
CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company's lead program for innate immunity, ADX-097
Read more →QTTBQ32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors
CAMBRIDGE, Mass., Aug. 3, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of expe
Read more →QTTBQ32 Bio Appoints Adam Cutler as Chief Financial Officer
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer. Mr. Cutler will be responsible for all aspects
Read more →QTTBQ32 Bio to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 27, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that Michael Broxson, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual
Read more →QTTBForward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relat
Corporate Presentation February 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of histo
Read more →QTTBHomology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc. BEDFORD, Mass., November 9, 2020 Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million equity investment in
Read more →QTTBHomology Medicines Appoints Alise Reicin, M.D., to the Board of Directors - Celgene Executive with Early- and Late-Stage Global Clinical Development Experience Joins as Homology Advances Lead Gene Therapy Program for PKU
Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors - Celgene Executive with Early- and Late-Stage Global Clinical Development Experience Joins as Homology Advances Lead Gene Therapy Program for PKU Through the Clinic - BEDFORD, Mass., July 15, 2019 Homol
Read more →QTTBHomology Medicines Announces Leadership Updates - Sam Rasty, Ph.D., Departs as Chief Operating Officer to Lead an Emerging Biotech
Homology Medicines Announces Leadership Updates - Sam Rasty, Ph.D., Departs as Chief Operating Officer to Lead an Emerging Biotech - BEDFORD, Mass., June 27, 2019 Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today changes to its leadership te
Read more →Competitive Position
How QTTB ranks across every disease it competes inCompetitive Position is a premium feature
See how QTTB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial